• About
  • Masthead
  • License Content
  • Advertise
  • Submit Press Release
  • RSS/Email List
  • Write for us
  • Contact us
2 Minute Medicine
No Result
View All Result

No products in the cart.

SUBSCRIBE
  • Specialties
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • Wellness
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • AccountLog-in/out
    • Subscribe
    • Sign-in
    • My account
2 Minute Medicine
  • Specialties
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • Wellness
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • AccountLog-in/out
    • Subscribe
    • Sign-in
    • My account
SUBSCRIBE
2 Minute Medicine
Subscribe
Home All Specialties Chronic Disease

Tumor size, chemoembolization response may predict hepatocellular carcinoma recurrence

byRehan SaiyedandChaz Carrier
May 9, 2014
in Chronic Disease, Gastroenterology, Oncology
Reading Time: 3 mins read
0
Share on FacebookShare on Twitter

Image: PD 

1. In patients with hepatocellular carcinoma who underwent liver transplantation, response to transarterial chemoembolization and radiologic size of tumor were both shown to independently predict rates of recurrence. 

2. Patients with no response to chemoembolization and a radiologic tumor size greater than 3 cm had a recurrence rate of 35.8% compared with 1.9% for patients responding to chemoembolization and a tumor size less than 3 cm. 

Evidence Rating Level: 2 (Good) 

Study Rundown: Liver transplantation has played an increasing role in the treatment of hepatocellular carcinoma (HCC). Recurrence following transplantation remains an issue, however, and pre-operative identification of patients at a higher risk for recurrence is limited. This study aimed to identify pre-operative factors to predict rates of HCC recurrence in patients after liver transplantation. Through multivariate analysis, the authors found that a lack of tumor responsiveness to transarterial chemoembolization (TACE) and radiologic tumor size greater than 3 cm were both independent predictors of HCC recurrence. Vascular invasion of the tumor had the strongest association with recurrence but such information is not known pre-operatively, limiting its predictive value. This study provides a means by which to identify patients who are at higher risk of HCC recurrence following liver transplantation. The true utility of such pre-transplant identification is limited by the ethical dilemma in preferentially selecting patients for transplants who lie in the theoretical “lower-risk” group.  That said, there is certainly value in identifying patients with a high risk of recurrence as it would allow for more extensive pre-transplant therapy. This study is limited by selection bias imposed by its retrospective nature as only patients who were treated with TACE and had sufficient time for pre-transplantation radiologic follow-up were included in the analysis.

Click to read the study in the American Journal of Transplantation

Relevant Reading: Hepatocellular carcinoma: CT for tumor response after transarterial chemoembolization in patients exceeding Milan criteria–selection parameter for liver transplantation

RELATED REPORTS

#Visual Abstract Watchful waiting may be an appropriate strategy for some patients with basal cell carcinomas

#VisualAbstract GHSG HD14: Intensified chemotherapy regimen (BEACOPP+ABVD) improved progression-free survival without improving overall survival over long-term follow-up

#VisualAbstract: Atezolizumab-bevacizumab treatment increases survival in unresectable hepatocellular carcinoma

In-Depth [retrospective cohort]: 173 patients with HCC who received a liver transplant were selected for inclusion into the study if they underwent pre-transplant TACE along with radiologic follow-up. Patient’s response to TACE was assessed using modified response evaluation criteria in solid tumors (mRECIST) and patients were accordingly grouped as “responders” or “non-responders.”  mRECIST response categories are organized by the extent of arterial invasion of the tumor. Response to TACE was shown to be predictive of HCC recurrence. 5-year recurrence was 5.3% in the “responder” group compared to 17.6% in the in the non-responders. Tumor size greater than 3 cm was also independently predictive of HCC recurrence. The rate of recurrence in patients who were non-responders to TACE and had a tumor size grater than 3 cm was 35.8%, 10.8% for patients who were non-responders but who had a tumor size less than 3 cm, 11.9% for patients who were responders with a tumor size greater than 3 cm, and 1.9% for patients who responded to TACE and had a tumor size less than 3 cm (log-rank, p=.0007).

More from this author: Decreased breast cancer recurrence and mortality following post-mastectomy radiotherapy, Increased incidence of stroke found after aortic valve replacement

©2012-2014 2minutemedicine.com. All rights reserved. No works may be reproduced without expressed written consent from 2minutemedicine.com. Disclaimer: We present factual information directly from peer reviewed medical journals. No post should be construed as medical advice and is not intended as such by the authors, editors, staff or by 2minutemedicine.com. PLEASE SEE A HEALTHCARE PROVIDER IN YOUR AREA IF YOU SEEK MEDICAL ADVICE OF ANY SORT.  

Tags: chemoembolizationhepatocellular carcinomatumor
Previous Post

Gender differences in white matter integrity may affect post-traumatic brain injury

Next Post

Exercise associated with decreased Cesarean risk

RelatedReports

#Visual Abstract Watchful waiting may be an appropriate strategy for some patients with basal cell carcinomas
StudyGraphics

#Visual Abstract Watchful waiting may be an appropriate strategy for some patients with basal cell carcinomas

September 17, 2021
#VisualAbstract GHSG HD14: Intensified chemotherapy regimen (BEACOPP+ABVD) improved progression-free survival without improving overall survival over long-term follow-up
StudyGraphics

#VisualAbstract GHSG HD14: Intensified chemotherapy regimen (BEACOPP+ABVD) improved progression-free survival without improving overall survival over long-term follow-up

May 1, 2021
#VisualAbstract: Atezolizumab-bevacizumab treatment increases survival in unresectable hepatocellular carcinoma
StudyGraphics

#VisualAbstract: Atezolizumab-bevacizumab treatment increases survival in unresectable hepatocellular carcinoma

May 29, 2020
Quick Take: Influence of HIV Infection on the Natural History of Hepatocellular Carcinoma: Results From a Global Multicohort Study
Gastroenterology

Atezolizumab-bevacizumab treatment increases survival in unresectable hepatocellular carcinoma

May 21, 2020
Next Post
Adolescents’ muscle strength associated with lower cardiometabolic risk

Exercise associated with decreased Cesarean risk

Hypercortisolemia in ICU patients is due to reduced cortisol metabolism, not increased production

Medical liability system presents hurdles to injured patients

Key predictors of recurrence and survival for Merkel Cell Carcinoma elucidated

Key predictors of recurrence and survival for Merkel Cell Carcinoma elucidated

License Our Award-Winning Physician-Written Medical News and Visual Abstracts

2 Minute Medicine is the leading authoritative medical news licensing service, and the only with reports written by practicing doctors.

LICENSE CONTENT

Get 2MM+ Premium Access

No ads & unlimited access to all current reports, over 9000 searchable archived reports, visual abstracts, Weekly Rewinds, and the online edition of The Classics Series™ textbook.

Subscription Options
2 Minute Medicine

2 Minute Medicine® is an award winning, physician-run, expert medical media company. Our content is curated, written and edited by practicing health professionals who have clinical and scientific expertise in their field of reporting. Our editorial management team is comprised of highly-trained MD physicians. Join numerous brands, companies, and hospitals who trust our licensed content.

Recent Reports

  • #VisualAbstract: Severe actinic keratosis and need for additional treatment are markers for an increased risk of cutaneous squamous cell carcinoma
  • Virtual yoga and meditation intervention may be associated with increased health-related quality of life
  • Wellness Check: Mental Health
License Content
Terms of Use | Disclaimer
Cookie Policy
Privacy Statement (EU)
Disclaimer

© 2021 2 Minute Medicine, Inc. - Physician-written medical news.

  • Specialties
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • Wellness
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • Account
    • Subscribe
    • Sign-in
    • My account

© 2021 2 Minute Medicine, Inc. - Physician-written medical news.